Patents by Inventor Rajiv Sharma

Rajiv Sharma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250041267
    Abstract: Present invention relates to development of compound of formula (I) for treatment of Cryopyrin Associated Periodic Syndromes (CAPS). Specifically, the present invention provides a NLRP3 inhibitors or its pharmaceutically acceptable salt for treatment of Cryopyrin Associated Periodic Syndromes (CAPS). Invention also relates to the pharmaceutical composition comprising compound of formula (I) or its pharmaceutically acceptable salts for treatment of Cryopyrin Associated Periodic Syndromes (CAPS).
    Type: Application
    Filed: July 8, 2022
    Publication date: February 6, 2025
    Inventors: Sameer AGARWAL, Deven V PARMAR, Binu PHILIP, Rajiv SHARMA, Mukut JAIN, Abhijit CHATTERJEE
  • Publication number: 20240327407
    Abstract: The present invention relates to compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as Autotaxin (ATX) inhibitors.
    Type: Application
    Filed: November 19, 2021
    Publication date: October 3, 2024
    Inventors: Rajiv SHARMA, Rajesh BAHEKAR, Vijay PRAJAPATI, Darshan JOSHI, Kamal DAVE
  • Publication number: 20240300899
    Abstract: The present invention relates to novel crystalline forms of a quinolone compound of Formula (I). The invention also relates to processes for the preparation crystalline forms of the compound of Formula (I). Further the disclosure provides a process for the preparation of compound of Formula (I), intermediates, impurities and pharmaceutical compositions thereof.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 12, 2024
    Inventors: Kumar Kamlesh SINGH, Rajiv SHARMA, Santosh Devidas DIWAKAR, Jitendra Maganbhai GAJERA, Sumer Singh CHUNDAWAT, Jayesh Anilkumar SHARMA
  • Patent number: 12084416
    Abstract: The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1? activity is implicated.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: September 10, 2024
    Assignee: Zydus Lifesciences Limited
    Inventors: Rajiv Sharma, Sameer Agarwal
  • Publication number: 20240122989
    Abstract: Provided herein are compositions, methods, and systems, comprising a programmable nucleic acid-guided nuclease and sequence-diverged donor sequences. The compositions and methods described herein facilitate editing of a targeted locus using a diverged sequence encoding for a functional protein product.
    Type: Application
    Filed: October 12, 2023
    Publication date: April 18, 2024
    Inventors: Beeke Wienert, Rajiv Sharma, Daniel Dever, Aishwarya Churi, Christopher Bandoro
  • Patent number: 11773077
    Abstract: The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: October 3, 2023
    Assignee: PIRAMAL ENTERPRISES LIMITED
    Inventors: Rajiv Sharma, Sanjay Kumar, Vishal Mahajan, Komal Bajaj, Pallavi Godse
  • Publication number: 20230096220
    Abstract: The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1? activity is implicated.
    Type: Application
    Filed: February 26, 2021
    Publication date: March 30, 2023
    Inventors: Rajiv SHARMA, Sameer AGARWAL
  • Publication number: 20230096663
    Abstract: Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
    Type: Application
    Filed: February 11, 2021
    Publication date: March 30, 2023
    Inventors: Robert Judkins, Lambertus Benthem, Rajiv Sharma
  • Publication number: 20230089247
    Abstract: The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation The present invention is directed towards compounds which can be useful in treating diseases such as Hyperlipidemia and also have a beneficial effect on lowering cholesterol.
    Type: Application
    Filed: December 24, 2020
    Publication date: March 23, 2023
    Inventors: Rajiv SHARMA, Sanjay KUMAR, Harikishore PINGALI, Suresh POLA, Pankaj MAKADIA, Prashant DESHMUKH, Pandurang ZAWARE, Kiran SHAH
  • Publication number: 20230089784
    Abstract: Provided herein are compositions, methods, and systems, comprising a programmable nucleic acid-guided nuclease and sequence-diverged donor sequences. The compositions and methods described herein facilitate editing of a targeted locus using a diverged sequence encoding for a functional protein product.
    Type: Application
    Filed: April 12, 2022
    Publication date: March 23, 2023
    Inventors: Beeke WIENERT, Rajiv SHARMA, Daniel DEVER, Aishwarya CHURI, Christopher BANDORO
  • Publication number: 20220313657
    Abstract: The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belongs to the family of NOD like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators and use of these novel inhibitor compounds in the treatment of disease or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1? activity and interleukin-18 (IL-18) is implicated.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 6, 2022
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Rajiv SHARMA, Sameer AGARWAL
  • Publication number: 20220169605
    Abstract: The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1? activity is implicated.
    Type: Application
    Filed: January 13, 2020
    Publication date: June 2, 2022
    Inventors: Rajiv Sharma, Sameer Agarwal
  • Publication number: 20220169603
    Abstract: Present invention relates to novel salts of saroglitazar and certain polymorphic forms of saroglitazar salts. Invention provides process for the preparation of novel salts and polymorphic forms of saroglitazar. Invention also provides novel co-precipitants or premixes of saroglitazar with pharmaceutically acceptable excipients/secondary therapeutic agent and process for the preparing same.
    Type: Application
    Filed: March 11, 2020
    Publication date: June 2, 2022
    Inventors: Rajiv Sharma, Sanjay Kumar, Brijesh Kumar Srivastava, Harikishore Pingali, Ranjeet Nair, Kalpesh Shah, Pandurang Zaware, Manoj Patel, Kamal Dave
  • Patent number: 11339153
    Abstract: Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR such as bile acid related disorders, metabolic syndrome, type-2-diabetes, hyperlipidemia, hypertriglyceridemia, primary biliary cirrhosis (PBC), fatty liver disease, nonalcoholic steatohepatitis (NASH), inflammatory autoimmune diseases, Crohn's disease, multiple sclerosis, atherosclerosis, kidney disorders (including chronic kidney disease), hepatic and colon cancers, and other disorders. The compounds are in the class of sulfinic acid compounds and can be an enantiomer, stereoisomer, tautomer, solvate, hydrate, prodrug, metabolite, or pharmaceutically acceptable salt thereof. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: May 24, 2022
    Assignee: Inorbit Therapeutics AB
    Inventors: Rajiv Sharma, Lambertus Benthem, Robert Judkins
  • Publication number: 20220145286
    Abstract: Methods and compositions for monitoring a plurality of independent genomic modifications in cell lineages are provided.
    Type: Application
    Filed: April 7, 2020
    Publication date: May 12, 2022
    Inventors: Daniel Dever, Rajiv Sharma, Matthew Porteus, Ravindra Majeti, Joab Camarena, Thomas Koehnke
  • Patent number: 11236045
    Abstract: The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1? activity and interleukin-18 (IL-18) is implicated.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: February 1, 2022
    Assignee: Cadila Healthcare Limited
    Inventors: Rajiv Sharma, Pravin Iyer, Sameer Agarwal
  • Publication number: 20210309656
    Abstract: Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
    Type: Application
    Filed: August 6, 2019
    Publication date: October 7, 2021
    Inventors: Rajiv Sharma, Lambertus Benthem, Robert Judkins
  • Patent number: 11084784
    Abstract: The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by ROR?.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: August 10, 2021
    Assignee: PIRAMAL ENTERPRISES LIMITED
    Inventors: Rajiv Sharma, Bichismita Sahu, Sunil Vasantrao Mali, Deepak Singh, Pramod Bhaskar Kumar, Mahesh Dawange, Hitesh Mistry
  • Patent number: 10941133
    Abstract: The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: March 9, 2021
    Assignee: PIRAMAL ENTERPRISES LIMITED
    Inventors: Rajiv Sharma, Sanjay Kumar, Vishal Mahajan, Komal Bajaj, Pallavi Godse
  • Publication number: 20210053938
    Abstract: The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.
    Type: Application
    Filed: November 2, 2020
    Publication date: February 25, 2021
    Inventors: Rajiv SHARMA, Sanjay KUMAR, Vishal MAHAJAN, Komal BAJAJ, Pallavi GODSE